3 High-Yield Dividend Stocks You Can Buy in September and Hold Forever

Core Insights - The article highlights the challenge of finding high-yield dividend stocks in a buoyant stock market, emphasizing the potential of Realty Income, Healthpeak Properties, and Pfizer as attractive options for passive income generation. Group 1: Realty Income - Realty Income has seen its shares fall approximately 22% from their peak in 2022, yet it continues to raise its dividend payout, currently offering a 5.5% yield with a history of steady payout growth [4][5]. - The company makes monthly dividend payments and has raised its payout every quarter except one since going public over 30 years ago, despite facing challenges from rising interest rates [5]. - Realty Income's portfolio consists of 15,606 properties, and it only accounts for about 4% of the U.S. net lease REIT market, indicating significant growth potential, especially in Europe where it has a minimal market share [6]. Group 2: Healthpeak Properties - Healthpeak Properties, a net lease REIT, focuses on renting laboratory space to pharmaceutical and biotech companies and recently merged with Physicians Realty to enhance its portfolio [7][8]. - Following the merger, Healthpeak's stock price has declined, allowing it to offer a 6.8% dividend yield, despite a decrease in demand for laboratory space [8]. - The company expects funds from operations to be between $1.78 and $1.84 per share this year, which is sufficient to support its current annualized payout of $1.22 per share [9]. Group 3: Pfizer - Pfizer's shares have decreased about 60% from their all-time high during the COVID-19 pandemic, primarily due to declining sales of COVID-19 products and upcoming patent cliffs [10]. - Despite the stock price drop, Pfizer raised its dividend for the 16th consecutive year, currently offering a 6.9% yield [10]. - The company anticipates losing patent protection for key products, which could reduce annual sales by $17 billion to $18 billion between 2026 and 2028, but it has invested in new products expected to generate $20 billion in annual sales by 2030 [11][12].